Resources Repository
-
ReportPublication 2017DCP3: Improving Health and Reducing Poverty
This report from the World Bank is the ninth and final volume of the Disease …
This report from the World Bank is the ninth and final volume of the Disease Control Priorities, Third Edition (DCP3) series. It provides an overview of the findings and methods explored in the first eight volumes, placing them within a framework that identifies an efficient pathway toward essential universal health coverage through the implementation of 21 essential packages that include health interventions and fiscal and intersectoral policies. The Disease Control Priorities Network (DCP) promotes and…
Evidence Synthesis | Economics/Finance | Policy/Regulation | Mental Health | Infectious Diseases | Costing Methods | Health Outcomes | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Injuries/Accidents | Social Determinants | Health Systems | Global Governance | Government/Law | Health/Medicine | Science/Technology | Global -
ArticlePublication 2022Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face …
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face of uncertainty. This study aimed to quantify consequences of approving therapies or pursuing further research. The authors used a cohort state-transition model for hospitalized patients with COVID-19 to estimate quality-adjusted life-years (QALYs) and costs associated with multiple drug regimens and usual care. For each they assessed immediate approval, use only in research, emergency use authorization or reject. They conducted cost-effectiveness…
Value of Information | Economics/Finance | Policy/Regulation | Infectious Diseases | State-Transition | Benefit-Cost Analysis | North America | Europe -
ReportPublication 2018Understanding the Economics of Microbial Threats: Proceedings of a Workshop
This report follows a June 2018, Forum on Microbial Threats that was held at the …
This report follows a June 2018, Forum on Microbial Threats that was held at the National Academies of Sciences, Engineering, and Medicine. This was a 1.5-day public workshop with the goal being an assessment of the current understanding of the interaction of infectious disease threats and economic activity in order to suggest future areas of research. This workshop built on prior work of the Forum and aimed to build more mutual understanding between those in…
Evidence Synthesis | Economics/Finance | Policy/Regulation | Infectious Diseases | Health Outcomes | Technology Assessment | Global Governance | Clinical Care | Business/Industry | Health/Medicine | Global -
ReportPublication 2010Priorities for the National Vaccine Plan
The authors examine the complexities of the vaccine enterprise, a fundamental component of preventive medicine …
The authors examine the complexities of the vaccine enterprise, a fundamental component of preventive medicine and public health, from research and development of new vaccines to financing and reimbursement of immunization services. The current climate, socially, economically and politically, presents challenges and opportunities to the U.S. to strengthen the existing systems of developing, manufacturing, regulating, distributing, funding, and administering safe and effective vaccines for all people. The authors present recommendations for priority actions intended to…
Evidence Synthesis | Economics/Finance | Policy/Regulation | Infectious Diseases | Technology Assessment | Chronic Disease/Risk | Health Systems | Health/Medicine | Science/Technology | North America -
Resource PackPublication, Teaching Resource 2017Resource Pack: Disease Control Priorities
This resource pack, curated by the Center of Health Decision Science, showcases selected analyses produced …
This resource pack, curated by the Center of Health Decision Science, showcases selected analyses produced by the Disease Control Priorities 3 (DCP3) to inform program design and resource allocation at the global and country levels. Analyses focus on the effectiveness, cost, and cost-effectiveness of priority interventions. Learn more by visiting the DCP3 website.
Evidence Synthesis | Economics/Finance | Mental Health | Infectious Diseases | Costing Methods | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Injuries/Accidents | Health Systems | Health/Medicine | Global | College | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Policy Translation | Quantitative Literacy -
Resource PackPublication, Teaching Resource 2017Resource Pack: U.S. Opioid Epidemic
Opioid misuse and addiction in the United States is an ongoing and rapidly evolving public …
Opioid misuse and addiction in the United States is an ongoing and rapidly evolving public health crisis, requiring an urgent coordinated response and innovative scientific solutions. This resource pack was curated for educators and students interested in how decision analytic methods and tools can be applied to the problem of opioid addiction.
Evidence Synthesis | Economics/Finance | Policy/Regulation | Mental Health | Preferences/Values | Mathematical Models | Decision Analysis | Cost-Effectiveness Analysis | Chronic Disease/Risk | Social Determinants | Health Systems | Government/Law | Health/Medicine | North America | College | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Decision Making/Leadership | Policy Translation -
BookPublication 1996Cost-Effectiveness in Health and Medicine, 1st Edition
In 1993, the US Public Health Service convened a panel of 13 nongovernment scientists and …
In 1993, the US Public Health Service convened a panel of 13 nongovernment scientists and scholars with expertise in economics, clinical medicine, ethics, and statistics to review the state of cost-effectiveness analysis and to develop recommendations for its conduct and use in health and medicine. Publishing their results in 1996, they proposed the most explicit set of guidelines (together with their rationale) ever defined on the conduct of CEAs. The panel recommended analysts include a "reference-case"…
Evidence Synthesis | Value of Information | Economics/Finance | Policy/Regulation | Preferences/Values | Priority Setting/Ethics | Costing Methods | Health Outcomes | Cost-Effectiveness Analysis | Health Systems | Health/Medicine | North America -
ArticlePublication 2022Comparative Health Systems Analysis of Differences in Catastrophic Health Expenditure
The growing burden of non-communicable diseases (NCDs) in low- and middle-income countries may have implications …
The growing burden of non-communicable diseases (NCDs) in low- and middle-income countries may have implications for health system performance in the area of financial risk protection, as measured by catastrophic health expenditure (CHE). This article compares non-communicable diseases catastrophic health expenditure to the CHE cases caused by communicable diseases across health systems to examine whether: (1) disease burden and catastrophic health expenditure are linked, (2) Catastrophic health expenditures secondary to NCDs disproportionately affect wealthier households and (3) whether the drivers…
Evidence Synthesis | Economics/Finance | Infectious Diseases | Costing Methods | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health Systems | Health/Medicine | Global -
ReviewPublication 2022Systematic Review of Economic Evaluations of COVID-19 Interventions: Non-Health Impacts and Distributional Issues
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether …
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether they incorporated non-health impacts and distributional concerns. Among the 70 articles included, more than half (56%) included at least one non-health impact, although only 21% incorporated non-economic consequences. Only 17% examined subgroups of interest. The median ICER for the entire sample was $67,000/quality-adjusted life-year (QALY) (interquartile range [IQR] $9000-$893,000/QALY). Interventions including a pharmaceutical component yielded a median ICER of $93,000/QALY (IQR…
Evidence Synthesis | Economics/Finance | Infectious Diseases | Cost-Effectiveness Analysis | Social Determinants | Culture/Society | Health/Medicine | North America